BridgeBio Pharma, Inc.
infigratinib
achondroplasia
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for infigratinib (achondroplasia) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“NDA and MAA submissions planned in second half of 2026 for achondroplasia”